Welcome to our dedicated page for Envista Holdings SEC filings (Ticker: NVST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envista Holdings Corporation (NYSE: NVST) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed information about its dental products business. As a Delaware-incorporated public company with common stock registered under Commission File Number 001-39054, Envista uses SEC filings to report on financial results, governance changes, and other material events related to its global family of dental brands.
On this page, investors can review Envista’s core periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s segments, such as Specialty Products & Technologies and Equipment & Consumables, along with risk factors, management discussion, and financial statements. Current reports on Form 8-K disclose specific developments, such as quarterly earnings releases, the publication of a Sustainability Report covering environmental, social, and governance topics, and changes in the composition of the Board of Directors.
Envista’s 8-K filings include items reporting results of operations and financial condition, where the company furnishes press releases detailing sales, net income, adjusted EBITDA, and business highlights for recent quarters. Other 8-K items address Regulation FD disclosures, such as slide decks used on earnings calls or references to sustainability and investor presentations, as well as board-level changes like the resignation of a director.
Through Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that explain key points in accessible language. Users can quickly identify the most relevant sections of Envista’s 10-K and 10-Q reports, understand the implications of 8-K announcements, and access information related to the company’s capital structure and governance. This page also serves as a starting point for tracking any future Forms 4 or proxy materials that may detail insider transactions or executive compensation, as they become available in Envista’s regulatory record.
Envista Holdings Corporation reported solid growth for the quarter ended April 3, 2026. Sales rose to $705.5 million, up from $616.9 million, with core sales increasing 9.5% on higher volume and pricing, especially in North America and Europe.
Net income more than doubled to $38.7 million from $18.0 million, and diluted EPS increased to $0.23 from $0.10. Gross margin improved to 55.3% as stronger volumes, pricing and favorable foreign exchange more than offset higher tariffs. Specialty Products & Technologies and Equipment & Consumables both expanded operating margins.
Envista closed the $54.7 million Versah acquisition to strengthen its implant portfolio and ended the quarter with $1,082.8 million in cash and cash equivalents and $1,439.1 million of long-term debt. After quarter-end, the board authorized a new $300 million stock repurchase program through December 31, 2029.
Envista Holdings Corporation reported strong first quarter 2026 results. Sales were $705.5 million, up 14.4% year-on-year, with 9.5% core sales growth. GAAP diluted EPS rose to $0.23 from $0.10, while adjusted diluted EPS increased 50% to $0.36.
GAAP net income was $38.7 million and adjusted EBITDA was $98.9 million, representing a 14.0% adjusted EBITDA margin, up 120 basis points. Operating cash flow was negative $3.3 million and free cash flow was negative $15.7 million. The company repurchased 1.6 million shares for about $43 million and the board approved an additional $300 million stock repurchase authorization through December 31, 2029.
Envista reaffirmed its 2026 outlook, targeting 2% to 4% core sales growth, 7% to 13% adjusted EBITDA growth, adjusted diluted EPS of $1.35 to $1.45, and approximately 100% free cash conversion.
Envista Holdings Corp ownership disclosure: Vanguard Capital Management reports beneficial ownership of 8,574,557 shares of Envista common stock, representing 5.23% of the class as of 03/31/2026. The filing states Vanguard holds sole dispositive power over those shares and identifies affiliated Vanguard entities that exercise voting or dispositive authority.
Envista Holdings Corporation is asking stockholders to vote at its 2026 virtual annual meeting on May 19, 2026. The agenda includes electing eight directors, ratifying Ernst & Young LLP as auditor, an advisory vote on executive pay, and a vote on how often to hold future pay advisory votes.
Envista reports 2025 total revenue of $2,719.5 million, up from $2,510.6 million in 2024, with total sales growth of 8.3% and core sales growth of 6.5%. Net income was $47.0 million versus a prior-year loss, and Adjusted EBITDA was $371.7 million with a 13.7% margin. Diluted earnings per share were $0.28, and Adjusted diluted EPS were $1.19.
The Board highlights strong governance practices, including an independent Chairperson, annual director elections, a majority-independent Board, and annual say-on-pay votes. Executive compensation emphasizes pay-for-performance with base salary, annual incentives tied to growth, profitability and cash flow, and long-term incentives focused on performance stock units, stock options and RSUs.
The Vanguard Group filed an amended Schedule 13G reporting that, following an internal realignment, it holds 0 shares of Envista Holdings Corp common stock, representing 0% of the class. The filing explains certain subsidiaries now report disaggregated beneficial ownership in reliance on SEC Release No. 34-39538, and that The Vanguard Group, Inc. no longer is deemed to have beneficial ownership over securities held by those subsidiaries. The amendment lists the issuer address as 200 South Kraemer Blvd, Brea, CA and the filer address as 100 Vanguard Blvd., Malvern, PA. The report is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.
Envista Holdings Corp Chief Financial Officer Eric D. Hammes reported multiple equity transactions. He received 29,225 Performance Share Units and 38,040 stock options that vest over three years, along with 16,055 restricted stock units that also vest annually over three years.
In a related tax-withholding transaction, 2,045 shares of common stock were withheld at $29.59 per share to cover taxes on vesting RSUs, rather than sold in the open market. After these transactions, his directly held common stock increased to 110,798 shares, with additional unvested equity awards outstanding.
Envista Holdings Corp reported insider equity awards for Veronica Acurio, President, Orthodontics. On the reported date, she received grants of 13,845 Performance Share Units and 18,020 stock options, along with a 7,605-share award of common stock in the form of restricted stock units.
The performance units may ultimately pay out between 0%-200% of the 13,845 target amount based on achievement of specified performance measures over a three-year period. The option grant and restricted stock units vest in equal installments on each anniversary of grant over three years, conditioned on continued service.
The filing also shows a disposition of 1,412 common shares at $29.59 per share to satisfy tax withholding obligations tied to vesting RSUs, a non-open-market transaction. After these transactions, Acurio directly held 56,516 shares of Envista common stock.
Envista Holdings Corp reported insider equity awards for executive Stefan Nilsson, President, Nobel Biocare. He received 13,845 Performance Share Units that may pay out from 0% to 200% of target based on three-year performance, and an option for 18,020 shares vesting over three years.
Nilsson was also granted 7,605 Restricted Stock Units, which vest ratably over three years and convert into common shares on a 1-for-1 basis. In a related move, 182 common shares were withheld and disposed of to cover tax obligations upon RSU vesting.
Envista Holdings Corp executive Mischa Reis reported mixed equity compensation activity. On February 25, Reis received 10,770 Performance Share Units that may vest over a three-year performance period, with actual payout ranging from 0% to 200% of this target amount based on performance certification.
On the same date, Reis was granted 14,020 stock options that vest in three equal annual installments, and 5,915 restricted stock units that also vest ratably over three years, each converting into one share of common stock. In connection with the vesting of previously granted RSUs, 2,976 shares of common stock were withheld at $29.59 per share to cover tax obligations, reducing open-market impact. After these transactions, Reis directly owned 35,321 shares of common stock.